PT1001B (a novel selective inhibitor of type I PRMTs) down-regulated PD-1+ leukocytes and reduced PD-L1 expression in a pancreatic cancer mouse model, which significantly improved the inhibition of tumor cell proliferation and apoptosis induction when combined with anti-PD-L1 (194). This evidence concerns the gene CD274 and neoplasm.